Banco Bilbao Vizcaya Argentaria S.A. Has $27.83 Million Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Banco Bilbao Vizcaya Argentaria S.A. cut its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 4.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 36,038 shares of the biopharmaceutical company’s stock after selling 1,587 shares during the quarter. Banco Bilbao Vizcaya Argentaria S.A.’s holdings in Regeneron Pharmaceuticals were worth $27,833,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the stock. WPG Advisers LLC grew its holdings in Regeneron Pharmaceuticals by 312.5% in the 4th quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 25 shares in the last quarter. Titan Wealth CI Ltd acquired a new stake in Regeneron Pharmaceuticals in the 4th quarter worth about $29,000. Board of the Pension Protection Fund acquired a new stake in Regeneron Pharmaceuticals in the 4th quarter worth about $31,000. Kemnay Advisory Services Inc. bought a new stake in Regeneron Pharmaceuticals in the 4th quarter valued at about $31,000. Finally, Entrust Financial LLC acquired a new position in shares of Regeneron Pharmaceuticals during the 4th quarter worth approximately $32,000. 83.31% of the stock is owned by institutional investors.

Insider Activity at Regeneron Pharmaceuticals

In other news, Director Arthur F. Ryan sold 100 shares of the stock in a transaction on Friday, May 1st. The stock was sold at an average price of $705.24, for a total value of $70,524.00. Following the completion of the transaction, the director directly owned 17,503 shares in the company, valued at approximately $12,343,815.72. This represents a 0.57% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 6.97% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ:REGN opened at $607.93 on Thursday. Regeneron Pharmaceuticals, Inc. has a 1 year low of $503.25 and a 1 year high of $821.11. The stock has a market capitalization of $64.27 billion, a price-to-earnings ratio of 14.81, a price-to-earnings-growth ratio of 1.35 and a beta of 0.25. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.57 and a quick ratio of 2.96. The company’s 50 day simple moving average is $683.13 and its 200 day simple moving average is $734.34.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share for the quarter, topping the consensus estimate of $8.91 by $0.56. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The firm had revenue of $3.61 billion during the quarter, compared to analysts’ expectations of $3.48 billion. During the same period in the prior year, the company earned $8.22 earnings per share. The company’s quarterly revenue was up 19.0% on a year-over-year basis. As a group, research analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.44 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, June 4th. Stockholders of record on Wednesday, May 20th were issued a $0.94 dividend. The ex-dividend date of this dividend was Wednesday, May 20th. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.6%. Regeneron Pharmaceuticals’s dividend payout ratio is 9.16%.

Analyst Ratings Changes

Several research analysts have recently commented on the stock. TD Cowen raised their target price on shares of Regeneron Pharmaceuticals from $880.00 to $960.00 and gave the stock a “buy” rating in a report on Thursday, April 23rd. Barclays reduced their price target on Regeneron Pharmaceuticals from $923.00 to $917.00 and set an “overweight” rating on the stock in a research report on Thursday, April 30th. Canaccord Genuity Group lowered their price objective on Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating on the stock in a research note on Tuesday, May 19th. Morgan Stanley upped their target price on Regeneron Pharmaceuticals from $769.00 to $796.00 and gave the company an “equal weight” rating in a research report on Friday, April 10th. Finally, Royal Bank Of Canada reduced their target price on Regeneron Pharmaceuticals from $762.00 to $707.00 and set a “sector perform” rating on the stock in a report on Monday, May 18th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and ten have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $792.65.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.